cyrilzakka/clinical-trials huggingface dataset:
Resonance Breathing Training for Long Covid-related Myocardial Injury

An investigation of the efficacy of resonance breathing training in the rehabilitation of patients with Long covid-related myocardial injury


Eligibility Criteria:
Inclusion Criteria:

1. Age between 18 and 60 years;
2. According to the WHO definition: one or more systemic involvement present 3 months after the diagnosis of a new crown infection, and at least 2 of these months cannot be explained by other diseases
3. 2D-STE suggestive of GLSAVG: -17% ≤ men ≤ -10%, -18% ≤ women ≤ -10%;
4. Consent for enrollment based on the degree of myocardial injury, as diagnosed by a clinician;
5. Signing the informed consent form with the consent of the patient or his/her family members

Exclusion Criteria:

* (1) Previous history of coronary atherosclerotic heart disease and heart failure; (2) Combination of severe arrhythmia or cardiogenic shock; (3) Combination of severe hypertension, hypertrophic cardiomyopathy, valvular disease of moderate or higher grade, acute myocarditis or pericarditis; (4) Combination of any disease that severely affects limb movement, such as musculoskeletal system disease or severe hepatic or renal insufficiency; (5) Combination of progressive malignant tumors, infectious diseases, bleeding disorders, autoimmune diseases, etc; Those who have serious mental illness and are unable to cooperate
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.


Eligibility Criteria:
Inclusion Criteria:

* Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy
* Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody
* Measurable disease defined by at least one of the following:

  1. Serum M-protein \>/= 0.5 g/dL by SPEP
  2. Urinary M-protein excretion \>/= 200 mg/24 hours by UPEP
  3. Serum immunoglobulin FLC \>/= 10 mg/dL (\>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
* ECOG performance status 0 -1
* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade \</= 1

Exclusion Criteria:

* Active plasma cell leukemia
* Amyloidosis
* Stem cell transplant with 12 weeks prior to enrollment, or active GVHD
* POEMS syndrome
* Any active uncontrolled bacterial, fungal, or viral infection
* Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment
* Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)
* Sub-Study A Only: Previous treatment with BCMA bispecific antibody
* Sub-Study B Only: Previous treatment with BCMA directed therapy
Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients

The purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function in chinese, and which one could be better.

Chronic kidney disease patients with hyperuricemia and glomerular filtration rate (GFR) 20-60 ml/min were treated by febuxostat or benzbromarone. Follow up the changes of serum uric acid, serum creatinine and GFR levels. Compare the effects on renal function of these two drugs.

Eligibility Criteria:
Inclusion Criteria:

Chronic kidney disease patients with glomerular filtration rate (GFR,20-60ml/min) who match one of the following criteria:

1. Gout
2. serum uric acid \> 480umol/L

Exclusion Criteria:

1. GFR\<20ml/min or GFR \>60ml/min
2. Liver dysfunction (Aspartate transaminase or/and alanine aminotransferase exceed 2 times of normal range)
3. Urinary tract obstruction
4. unstable angina, heart failure (stage III-IV, NYHA), new stroke, need diuretics for long-term treatment
5. Severe lung diseases or cancers
6. Pregnant woman or woman who prepare to be pregnant，nursing mothers
7. unable to sign informed consent form，or disagree with following-up
Repetitive Thinking in FibroMyalgia and Attentional Bias

Theoretical models of chronic pain hypothesize a privileged treatment of pain-related information that would be the basis of avoidance behaviors in chronic pain. This privileged treatment, also called attentional bias, has been found experimentally in chronic pain. Meta-analyses confirmed that but leaded the question of the difference found between bias in period of attention orientation and bias in period of maintained attention. One of the hypotheses is to consider one or more cognitive processes that would "fix" the attention around significant perceived problems and that would hinder the attentional disengagement and the reorientation of attention towards neutral or positive stimuli. In view of the scientific literature in psychopathology but also in chronic pain we think that the negative repetitive thoughts (RNT) variable is one of these processes. So the investigators want to better understand the difference of attentional bias at different moments of the attentional process by interrogating the Repetitive Thinking variable. More specifically the investigators test the Attentional Bias hypothesis in Fibromyalgia. Patient with Fibromyalgia will be recruited at the Pain Center of CHU-Amiens. Patients will complete different scales and also the visual probe task. First, the investigators hypothesize the attention bias for pain-related information in the FM group is correlated with the level of negative repetitive thinking in the maintained attention phase. Second, the investigators hypothesize the attention bias is more important in the attention maintenance phase (1250 ms) than in the attention orientation phase (500 ms).


Eligibility Criteria:
Inclusion Criteria:

Adults Patients inclusion criteria:

* 1990 ACR Criteria of FM
* Free and informed consent signed.
* French mother tongue spoken, written, read.
* Major person.

Exclusion Criteria:

* Adult major under protection.
* Patient with severe psychosis or depression or severe anxiety or impulsivity as -assessed by the clinician.
Virtual Game Simulation in Patient Safety

With the development of technology, virtual game simulation is starting to take an important place in nursing education, which has spread to the virtual world. There are studies conducted with this application, but there are no virtual game simulation studies related to patient safety. The planned study aims to measure nursing students' tendencies and attitudes towards medical errors, satisfaction and self-confidence in nursing practices with a virtual game simulation related to patient safety developed by the researcher.

Simulation, also defined as activities that imitate clinical practices and simulation, are applications that provide competency-based clinical experience in a realistic environment that does not carry the risk of the real situation and is of great importance in terms of patient safety. Virtual game simulation, which includes technology and is one of the simulation applications, is a two-dimensional virtual computer game that includes simulated real people and allows students to actively participate in a clinical scenario. While the use of virtual game simulation in nursing education increases students' critical thinking, decision-making and problem-solving skills, it also provides learning by making mistakes and correcting mistakes by increasing individual development. The use of virtual game simulation in nursing education is necessary and important in ensuring and protecting patient safety. Virtual games, whose main purpose is to learn, have the potential to increase student participation, role-play difficult situations, try new reactions or work on creative solutions.

Eligibility Criteria:
Inclusion Criteria:

* Having taken the Fundamentals of Nursing course,
* Being willing and eager to participate in the study,
* Completing the Data Collection Forms completely,
* Not having any communication problems related to vision or hearing,
* Completing all stages of the simulation training process.

Exclusion Criteria:

* Not having received simulation training regarding patient safety.
Cannabidiol Into Breastmilk

Really few data published to date on the passage of CBD into breast milk. The investigators known that 17.5 percent of the French human being between 18 and 34 years old consume CBD and among this, nearly half are women. None official French data to say how many French breastfeeding mothers consume CBD. CBD is a legal, psychoactive but not psychoaddictive substance. CBD's pharmacokinetic and pharmacodynamics make us fear that CBD could easily go through mother's milk. No published data available on possible effect in breast-fed child, not even on possible biological passage in breast-fed child. The aim of his study is to evaluate the passage of CBD in blood and milk at different moments of the breastfeeding (mothers) and its possible found in the infants'urine.


Eligibility Criteria:
Inclusion Criteria:

* Women over 18
* Breastfeeding CBD user
* Having given written informed consent

Exclusion Criteria:

* Women who do not understand French well
* Women with a psychiatric or dual pathology that prevents proper participation in the study,
* Women under protective supervision (guardianship/curatorship),
* Women under court protection,
* Women not affiliated to a social security scheme
Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC)

Cohort CNC-PPNAD will be investigated with clinical, genetic, biological and imaging work-up every year during 3 years. Cohort L-MC will be investigated clinically at inclusion and a PERKAR1A genotype will be performed.

The primary aim is to assess the clinical manifestations of the CARNEY Complex (CNC) and/or the primary pigmented nodular adrenocortical disease (PPNAD) in patients with CNC, isolated PPNAD or carriers of PRKAR1A and PPNAD1 (PDE11A4) germline mutation (Cohort CNC-PPNAD). In this cohort genotype/phenotype correlation will be studied. A second aim is to determine the frequency of PRKAR1A germline mutation in patients with isolated cardiac myxoma or isolated lentiginosis (Cohort L-MC).

Eligibility Criteria:
Inclusion Criteria:

CNC group :

* patient with the CARNEY complex (CNC) or the primary pigmented nodular adrenocortical disease (PPNAD) or a germinal mutation of the gene of CARNEY Complex or PPNAD.
* No age criteria
* Inform consent of the patient or the parental authority collected
* Realization of a preliminary medical examination
* Affiliated with a social security system ( profit or having right)

MC-L group :

* Patient with periorificial lentiginosis or cardiac myxoma
* or previous history of periorificial lentiginosis or cardiac myxoma
* age \> or = 18 years old
* Realization of a preliminary medical examination
* Affiliated with a social security system ( profit or having right)

Exclusion criteria :

CNC group and MC-L group:

* refusal or incapacity to take part in the study
Ropivacaine Versus Ropivacaine Plus Mepivacaine for Sciatic Block

In loco regional anesthesia, much more than for general anesthesia, the choice of the product is largely left at the discretion of the practitioner. Two categories of local anesthetics are distinguished according to their pharmacodynamic characteristics: products with a short time of installation and a short duration period, and products with a longer delay of installation of the sensitive and motor block, but with a long-term duration. Indeed, the combined use of two products pharmacodynamically different seems to be of a practical interest.

This study provides a comparison of the onset of action of 30 ml of ropivacaine 0.75% and 30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5% for the subgluteal sciatic nerve block. This is a prospective randomized double-blind study where the main criterion of judgment is the time of installation of a sensitive block compatible with surgery in the sciatic territory nerve. Fifteen patients per group were calculated to detect a 50% decrease of the onset of action in the combination group with a power of 90% and alpha to 5%, according to a previous pilot study. The secondary endpoints are the intensity and time of installation of the motor block, the duration of sensitive and motor block, the total dose of morphine administered within 48 hours, as well as its possible side effects.


Eligibility Criteria:
Inclusion Criteria:

* age \> 18 years
* surgery of the foot under sciatic block

Exclusion Criteria:

* no indication of locoregional anesthesia
* polyneuropathy or any neurological disease
* know hypersensitivity to local anesthetics
* porphyria
* atrio-ventricular block
* not controlled epilepsia
* hypovolemia
* pregnancy
* anticoagulant treatment
Brain Glucose Metabolism During Transcranial Direct Current Stimulation

With this study we will be able to dose-dependently measure real-time glucose metabolism changes after non-invasively stimulating superficial parts of the dlPFC, a commonly used target in therapeutic tDCS applications. This will provide further insight if and how tDCS is capable to change one of most reliable parameters of brain metabolism.

With this study, we will be able to substantiate if regional and whole brain glucose metabolism is affected by tDCS, assess the amount of signal change in relation to different currents and measure differences in glucose metabolism under stimulation reactivity between healthy subjects and depressive patients. The objective is to investigate the changes of regional cerebral metabolic rate of glucose (rCMRglu) in the brain after transcranial direct current stimulation in healthy subjects and depressive patients. The design is a cross-sectional proof of principle study in 20 healthy subjects and 20 depressed patients. During the PET scan tDCS will be applied with varying stimulus intensity. Furthermore, subjects will undergo a second PET scan with single-blind sham stimulation in order to validate the effects of tDCS. rCMRglu will be quantified using voxel-wise and ROI-based approaches. Changes in rCMRglu associated with tDCS-application will be calculated with a general linear model in a ramp function of the task-specific glucose uptake, according to previous work in our group. Exploratory statistical testing will be done using a paired samples t-test between task and rest conditions.

Eligibility Criteria:
Inclusion Criteria:

Healthy controls:

- Aged 18 to 55 years Somatic and psychiatric health based on medical history, physical examination, ECG, laboratory screening, SCID-I and II Willingness and competence to complete the informed consent process

Depressed Patients:

Current major depressive episode during unipolar major depression (MD) according to SCID-I (with HAMD\>17) No other concomitant axis-I disease apart from anxiety disorder, which must be secondary to MD Standard antidepressant medication stable during the last 4 weeks

Exclusion Criteria:

* Concomitant major medical or neurological illness, including history of seizures Any current substance abuse disorder according to DSM-V (urinary test and history) including current sedative usage in MDD patients ECT, TMS or NMDA-antagonists (ketamine) during the past 6 months. Current augmentation with anti-epileptics, or other drugs affecting seizure threshold Failure to comply with the study protocol or follow the instructions of the investigators Pregnancy Participants with previous total radiation exposure dose of 30mSv over the last 10 years (according to legislation on radiation protection).

Left-handedness
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome

The purpose of study is to evaluate the efficacy of the electrical muscle stimulation (EMS) device in patients with patellofemoral pain known as anterior knee pain. Usual treatment for it is physical therapy (PT). We want to evaluate and see if adding the electrical muscle stimulation will fasten the recovery and improved outcome in patellofemoral pain syndrome. Half of participants will receive EMS and PT while other half will receive PT only.

The patellofemoral pain syndrome also known as anterior knee pain is a common entity in young athletic population. In patellofemoral knee syndrome, one of the theory is that the vastus medialis obliquus muscle is weak. To strengthen the muscle, physical therapy exercises are commonly used. This study evaluates addition of the electrical muscle stimulation device.The electrical muscle stimulation device "Flex MT Plus" (Electrostim Medical Services Inc. Tampa, FL) is a FDA approved device and has been used in knee for other conditions like treating for weakness associated with knee injuries or after knee surgeries. It has shown to improve the outcomes in above mentioned conditions. Its efficacy has been tested in patellofemoral pain syndrome but in smaller sample size. We intend to test it in larger sample size patient population.

Bily et al (2008) (reference #1) published their results on patellofemoral pain syndrome comparing EMS +PT to PT only and found that overall significant improvement in outcome score in all patients but when compared between the groups there was no difference. But there sample size was 19 patients in each group. Small sample size was one of the limitation of their study. We intend to collect 46 patients in each group to find significant difference based on power analysis.

Eligibility Criteria:
Inclusion Criteria:

* Bilateral/unilateral anterior knee pain for more than 3 moths
* Age of patient 18 to 40 years
* At least 3 of the 4 following criteria present: pain associated with prolonged sitting with knees bend, pain with going downstairs, kneeling and squatting or sports activities
* No h/o injury
* No h/o surgery to the knee

Exclusion Criteria:

* H/o patellar dislocation or subluxation
* Associated bursitis, tendinitis in periarticular area
* Ligamentous problems
* Intra-articular pathology
* Pregnancy (patient reported pregnancy, in case of doubt patient will be referred to their OBG/GYN physician to exclude the pregnancy)
* H/o knee surgery
* Oral or intraarticular administration of steroid medication with in last 3 months
* Patients with implanted devices like pacemaker
Effects of Pomegranate Seed Oil and Mediterranean Diet on MCI

A double-blind clinical trial of pomegranate oil and Mediterranean diet that will be carried out on 60 patients with Mild Cognitive Impairment (MCI) and APOE ε3 and ε4 allele.

The aim of the research is to examine if the Mediterranean diet with pomegranate oil and without it can bring positive changes in patients with MCI in terms of motor and cognitive skills.

OBJECTIVES OF THE TRIAL

The objectives of this study are:

To investigate the efficacy of Mediterranean diet and Pomegranate oil as a disease course modifying treatment for MCI.

STUDY DESIGN This is a Greek, controlled double-blind trial of two compared groups, one with Mediterranean diet and one with Mediterranean diet and pomegranate oil. Qualifying patients will be assigned to receive 0.15 mL of pomegranate oil every day with Mediterranean diet at one group and at the other group will not. A Mediterranean dietary protocol will be given on a daily basis for 12 months at both groups.

Duration The total study duration will be 12 months. The recruitment will be about 6 months and the statistics and the preparation of the paper other 6 months.

Number of Subjects:

Sixty (60) subjects total will be enrolled.; Thirty (30) in the A group (Pomegranate oil + Mediterranean Diet); Thirty (30) in the B Group (Mediterranean Diet).

Patient identification:

Initials (First initial of first name and First initial of surname), date of birth and Patient Identification Number from database empedocles.

Eligibility Screening Form (ESF) : Checklist of inclusion and exclusion criteria Eligibility Statement: for patients found to be ineligible, the reason for ineligibility must be stated and Written informed consent will be obtained from the subjects which are eligible. The informed consent form must be co-signed by the physician. The nature of the study and the potential risks associated with the trial will be explained to all subjects- candidates and their responsible informants.

Signature and date: the ESF may be completed by a research assistant but it is required that the principal investigator/study clinician sign and date the ESF to verify eligibility of the patient for inclusion.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of Mild Cognitive Impairment
* Carry APOE ε3 or ε4 genes

Exclusion Criteria:

* Diagnosis of Dementia
* Patients who receive medication for memory or depression
* Patients who do not carry APOE ε3 or ε4 genes
Long Term Follow-up of Persistent Pain, Sensory Disturbances and Lymphedema After Breast Cancer Treatment

Persistent pain, sensory disturbances, lymphedema and functional impairment are frequently occurring late effects of breast cancer treatment. The investigators have previously published data on 3253 women treated for breast cancer in Denmark in the period 2005-2006. Very few studies have examined how these late effects change in time. The aim of this study is to examine in a well defined patient population any change in the prevalence of persistent pain, sensory disturbances, lymphedema and functional impairment, as well as risk factor profile.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with primary breast cancer between 2005-2006
* Participated in a study in 2008

Exclusion Criteria:

* Recurrent or new primary cancer
* Metastatic cancer
* Reconstructive surgery
Validation of Bispectral Index (BIS)-Monitor in 3 Groups of Newborn Children

This study will evaluate the registration of the bispectral index and spectral edge frequency in relation to the behavioural state.


Eligibility Criteria:
Inclusion Criteria:

* Group 1: normal healthy term newborns
* Group 2: Ill term newborns without brain damage
* Group 3: Preterm newborns without brain damage

Exclusion Criteria:

* Abnormal brain ultrasound
* Abnormal neurological examination
* Major congenital abnormalities
* Use of analgesics, sedatives, antiepileptic drugs or curarisation
Beta-2 Polymorphisms and Beta Receptor Selectivity

We hypothesize that b2 adrenergic polymorphisms affect b-receptor selectivity in patients with heart failure treated with either a b1-selective or a b-nonselective agent. b-2 polymorphisms may contribute to differing responses to drug treatment with beta-blockers in heart failure. Characterizing these polymorphisms may help explain the variability in the degree of "selectivity" of action of b-blockers at the b receptor, namely if their action is specific for the b-1 or b-2 receptor. Part A was conducted at the University of Utah, and all subjects completed study related activities. Part B (sub-study) consists of genotyping of blood samples collected in part A, which will be completed at the University of Wisconsin. Sub-study (samples and DNA isolation) or Part B entailed analyzing an extra 10 mL of blood that was taken for DNA isolation. Genotyping (i.e. determination of genetic makeup) of beta adrenergic polymorphisms utilized polymerase chain reaction followed by pyrosequencing.


Eligibility Criteria:
Inclusion Criteria:

* systolic dysfunction with ejection fraction ≤40%
* symptomatic heart failure class 2-3
* \>18 years of age
* optimal medical therapy of HF excluding the use of any beta-blockers within the previous 30 days of the study

Exclusion Criteria:

* active myocarditis
* hemodynamically significant valvular heart disease
* hypertrophic cardiomyopathy
* contra-indications to beta-blockers
* concomitant use of beta-agonists
* beta-antagonist or anti-arrhythmics
* unstable angina
* myocardial infarction or bypass surgery within 3 months
* significant renal insufficiency \[creatinine \>2.5 mg/dL\], liver disease, or anemia